ELAN vs. NBIX: Elanco Animal Health vs. Neurocrine Biosciences Stock Comparison

Company Profile

Elanco Animal Health (ELAN) and Neurocrine Biosciences (NBIX) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ELAN is classified in Pharmaceuticals while NBIX is classified in Biotechnology.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Elanco Animal Health (ELAN) has an aggressive beta of 1.65, indicating higher sensitivity to broad-market moves, while Neurocrine Biosciences (NBIX) is defensive at 0.29 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Capital efficiency shows on one side only: Neurocrine Biosciences (NBIX) earns 20.42% on shareholders’ equity, ranked against its industry; Elanco Animal Health (ELAN) has no ROE this period.

Elanco Animal Health (ELAN) reports a negative net margin of -2.86%, usually indicating a net loss over the period. Meanwhile Neurocrine Biosciences (NBIX) reports 18.98%, ranking against industry peers normally.

Neurocrine Biosciences (NBIX) at 31.98% operates in the top operating margin quartile, ahead of Elanco Animal Health (ELAN) at 6.64%, which runs around its industry’s norm.

Profitability Metrics

Growth

Both Elanco Animal Health (ELAN) at 6.22% and Neurocrine Biosciences (NBIX) at 21.45% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Neurocrine Biosciences (NBIX) at 41.95% is around its peer norm for EPS growth, while Elanco Animal Health (ELAN) at -169.12% drops into the bottom quartile, signaling weaker earnings momentum.

Growth Metrics

Financial Strength

Short-term liquidity can only be read on one side of this pairing: Neurocrine Biosciences (NBIX) shows current ratio of 2.04 against its industry benchmark, while Elanco Animal Health (ELAN) has no reading this period.

Both Elanco Animal Health (ELAN) at 0.64 and Neurocrine Biosciences (NBIX) at 0.12 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Neither Elanco Animal Health (ELAN) nor Neurocrine Biosciences (NBIX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Elanco Animal Health (ELAN) nor Neurocrine Biosciences (NBIX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Neurocrine Biosciences (NBIX) trades at 24.43 times trailing earnings, ranked against its peers, while Elanco Animal Health (ELAN) has no P/E ratio this period.

Elanco Animal Health (ELAN) at 2.50 sits in the cheaper P/S ratio quartile while Neurocrine Biosciences (NBIX) at 4.50 prices around its industry’s middle — ELAN costs less per dollar of sales, though read it alongside growth and margins.

On P/B ratio, both Elanco Animal Health (ELAN) at 1.95 and Neurocrine Biosciences (NBIX) at 4.30 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics